medroxyprogesterone acetate has been researched along with Leukemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunce, C; Chong, MG; Davies, N; Drayson, M; Farmer, R; Gunther, U; Hayden, R; Khanim, F; Pararasa, C; Ride, J; Rigoreau, L; Trivier, E; Veerapen, N; Veliça, P; Winn, P | 1 |
| Bunce, CM; Constantinou, JK; Drayson, MT; Hayden, RE; Khanim, FL; Koczula, KM; Michell, RH; Southam, AD; Viant, MR | 1 |
| Aracil, M; Jimeno, JM; Márquez, G; Quesada, AR | 1 |
3 other study(ies) available for medroxyprogesterone acetate and Leukemia
| Article | Year |
|---|---|
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxyprostaglandin Dehydrogenases; Leukemia; Male; Mass Spectrometry; Medroxyprogesterone Acetate; Prostatic Neoplasms; Substrate Specificity | 2014 |
Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bezafibrate; Cell Line, Tumor; Fatty Acids, Monounsaturated; HL-60 Cells; Humans; K562 Cells; Leukemia; Lipid Metabolism; Lymphoma; Medroxyprogesterone Acetate; Prognosis; Stearoyl-CoA Desaturase | 2015 |
Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line; Doxorubicin; Hematopoietic Stem Cells; Humans; Leukemia; Medroxyprogesterone Acetate; S Phase; Tumor Cells, Cultured | 1993 |